---
title: "Assembly Bio to expand ABI-6250 into PBC and PSC; Phase 2 HDV trial set for Q4 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287353780.md"
description: "Assembly Bio is expanding the development of ABI-6250 into primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), while also advancing its Phase 2 trial for hepatitis D virus (HDV) set for Q4 2026. The company has engaged with the FDA regarding its plans for cholestatic liver diseases, with a Phase 2 basket study in PBC and PSC expected in Q1 2027, pending regulatory feedback."
datetime: "2026-05-22T11:23:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287353780.md)
  - [en](https://longbridge.com/en/news/287353780.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287353780.md)
generator: "portal-rs"
---

# Assembly Bio to expand ABI-6250 into PBC and PSC; Phase 2 HDV trial set for Q4 2026

**Assembly Bio announced expansion of ABI-6250 development into cholestatic liver diseases, targeting PBC and PSC while advancing Phase 2 HDV plans.**

**Key Highlights:**

-   Plans to expand ABI-6250 from HDV into primary biliary cholangitis and primary sclerosing cholangitis.
-   ABI-6250 inhibits NTCP, blocking bile acid uptake—mechanism relevant to cholestatic disease pathology.
-   Phase 1a showed target engagement (dose-dependent plasma bile acid elevations); chronic tox supports longer dosing.
-   Phase 2 in HDV planned for Q4 2026; Phase 2 basket study in PBC and PSC expected Q1 2027, subject to regulatory feedback.
-   Company held a constructive pre-IND meeting with FDA to discuss development in cholestatic liver diseases.

Original SEC Filing: ASSEMBLY BIOSCIENCES, INC. \[ ASMB \] - 8-K - May. 22, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ASMB.US](https://longbridge.com/en/quote/ASMB.US.md)

## Related News & Research

- [Key facts: Assembly Biosciences Offers; ABI-6250 Expanded to PBC/PSC](https://longbridge.com/en/news/287422492.md)
- [Assembly Biosciences Prices 3.35 Mln Shares At $26.50/shr; To Expand ABI-6250 Development; Stock Up](https://longbridge.com/en/news/287364187.md)
- [Jensen Huang Says AI CEOs May Have 'Ulterior', Maybe 'Political' Reasons For AI Doomsday Warnings: 'Go and Read Between The Lines'](https://longbridge.com/en/news/299637656.md)
- [Michael Saylor Says, 'A Little More Orange': Will Strategy Report BTC Purchases After Hitting Pause for 3 Weeks?](https://longbridge.com/en/news/299601303.md)
- [Micron Stock's (MU) AI Lead Is Expanding beyond HBM. I'm Bullish](https://longbridge.com/en/news/299626350.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**